Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye
An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye
Sponsor: Cross Research S.A.
This PHASE2 trial investigates Dry Eye Syndrome and is currently completed. Cross Research S.A. leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2024 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2023 — May 2024 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Dec 2021 — Jan 2023 [monthly]
Completed PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2019 — Aug 2020 [monthly]
Completed PHASE2
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Completed PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cross Research S.A.
- Dompé Farmaceutici S.p.A
For direct contact, visit the study record on ClinicalTrials.gov .